Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 4, 2009, Pages 722-726

  Yoshimura, Reiji ^a   Hori, Hikaru ^a   Ikenouchi Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Ueda, Nobuhisa ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Antidepressant; Brain derived neurotrophic factor; Depression; Interleukin 6; Tumor necrosis factor

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUVOXAMINE; INTERLEUKIN 6; MILNACIPRAN; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; STATISTICS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 67349120985     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.03.020     Document Type: Article

References (48)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition (1994), American Psychiatric Association, Washington, DC
2. Berk M., Wadee A.A., Kuschker R.H., and O Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res 43 (1997) 529-534
3. Blier P., and Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 59 (1998) 16-23
4. Bodkin J.A., Lasser R.A., Wines J.D., Gardner D.M., and Baldessarini R.J. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 58 (1997) 137-145
5. Bull, S.J., Huezo-Diaz, P., Binder, E.B., Cubells, J.F., Ranjith, G., Maddock, C., et al., Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry, in press.
6. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune mediated inflammation. N Engl J Med 332 (1995) 1351-1362
7. Dentino A.N., Piper C.F., and Rao K.M.K. Association of interleukin-6 and other biological variables with depression in older people living in the community. Am J Geriatr Soc 47 (1999) 6-11
8. Dinan T.G., Lavelle E., Cooney J., Burnett F., Scott L., Dash A., et al. Dexamethasone augmentation in treatment-resistant depression. Acta psychiatr Scand 95 (1997) 58-61
9. Duman R.S., Malberg J., Nakagawa S., and D Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 48 (2000) 732-739
10. Durman R.S., Heninger G.R., and Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 54 (1997) 597-605
11. Figurov A., Pozzo-Miller L.D., Olafsson P., Wang T., and Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381 (2006) 706-709
12. Frommberger U.H., Bauer J., Haselbauer P., Franklin A., Riemann D., and Berger M. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247 (1997) 228-233
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
14. Harker L.A., Roskos L.K., Marzec U.M., Carter R.A., Cherry J.K., Sundell B., et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95 (2000) 2514-2522
15. Hayley S., Poulter M.O., Merali Z., and Anisman H. The pathogenesis of clinical depression: stressor-and cytokine-induced alteration of neuroplasticity. Neuroscience 135 (2005) 659-678
16. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., et al. Depression, comorbidities and the TNF-α system. Eur Psychiatry 23 (2008) 421-429
17. Hong C.J., Yu Y.W., Chen T.J., and Tsai S.J. Interleukin-6 gene polymorphism and Chinese major depression. Neeuropsychobiol 52 (2005) 202-205
18. Joffe R.T. The use of thyroid supplements to augment antidepressant medication. J Clin Psychiatry 59 (1998) 26-29
19. Kahl K.G., Greggersen W., Rudolf S., Stoeckelhuber B.M., Bergmann-Koester C.U., Dibbelt L., et al. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom Med 68 (2006) 669-674
20. Kelsey J.E. Switching drug class after initial SSRI failure. J Clin Psychiatry 583 (1997) 26-32
21. Kronfol Z. Depression and immunity: the role of cytokines. In: Plotnikoff N.P., Faith R.E., Mungo A.J., and Good R.A. (Eds). Cytokines stress and immunity (1999), CRC Press, Boca Raton
22. Kronfol Z., and Remick D.G. Cytokines and the brain implications for clinical psychiatry. Am J Psychiatry 157 (2000) 683-693
23. Lommatzsch M., Zingler D., Schuhbaeck K., Schloetcke K., Zingler C., Schuff-Werner P., et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 26 (2005) 115-123
24. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19 (1995) 11-38
25. Maes M. The immune pathophysiology of major depression. In: Honing A., and van Praag H. (Eds). Depression neurobiological psychophathological and therapeutic advances (1997), Wiley, Chester 197-215
26. Maes M., Verkerk R., Bonaccorso S., Ombelet W., Bosmans E., and Scharpe S. Depressive and anxiety symptoms in the early peurperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 71 (2002) 1837-1848
27. Marano C.M., Phatak P., Vemulapalli U.R., Sasan A., Nalbandyan M.R., Ramanujam S., et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 68 (2007) 512-517
28. Mastorakos G., Weber J.S., Magiakou G.A., Gunn H., and Chrousos G.P. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vaspressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 79 (1994) 934-939
29. Mitoma M., Yoshimura R., Sugita T., Umene W., Hori H., Nakano H., et al. Stress at work alters serum brain-derived neurotrophic factor (BDNF) and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress ?. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 679-685
30. Morikawa O., Sakai N., Obara H., and Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349 (1998) 317-324
31. Mossner R., Heils A., Stober G., Okladnova O., and Lesch K.P. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interferon-6. Neurochem Int 33 (1998) 251-254
32. Murphy P.G., Borthwick L.A., Altares M., Gauldie J., Kaplan D., and Richardson P.M. Reciprocal actions of interleukin-6 and brain derived neurotrophic factor on rat and mouse primary sensory neurons. Eur J Neurosci 12 (2000) 1891-1899
33. Nemeroff C.B. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 66 suppl 8 (2005) 13-21
34. O' Brien S.M., Scott L.V., and Dinan T. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Him Psychopharmacol 19 (2004) 397-403
35. O' Brien S.M., Scully P., Fizgerald P., Scott L.V., and Dinan T. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 41 (2007) 326-331
36. Podusto J.F., and Curran G.L. Permeability at the blood-brain and blood nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Mol Brain Res 36 (1996) 280-286
37. Roullion F., and Gorwood P. The use of lithium augment antidepressant medication. J Clin Psychiatry 59 (1998) 32-39
38. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57 (2000) 925-935
39. Schiepers O.G.J., Wichers M.C., and Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 201-217
40. Sen S., Duman R., and Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analysis and implications. Biol Psychiatry 64 (2008) 527-532
41. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 suppl 20 (1998) 34-57
42. Shelton R.C. Cellular mechanisms in the vulnerability to depression and response to antidepressants. Psychiatr Clin North Am 23 (2000) 713-729
43. Shoval G., and Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15 (2005) 319-329
44. Sluzewka A., Rybakowski J., Bosmans E., Sabieska M., Berghmans R., Maes M., et al. Indications of immune activation in major depression. Psychiatry Res 64 (1996) 161-167
45. Trivedi H.M., Rush A.J., and Wisniewski S.R. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163 (2006) 28-40
46. Yoshimura R., Umene-Nakano W., Ueda N., Ikenouchi-Sugita A., Hori H., and Nakamura J. Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline. Hum Psychopharmacol 23 (2008) 707-713
47. Yoshimura R., Mitoma M., Sugita A., Hori H., Okamoto T., Umene W., Ueda N., et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 1034-1037
48. Zhu C.B., Blakely R.D., and Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacol 31 (2006) 2121-2131